ARWR - Arrowhead Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
13.05
-0.30 (-2.25%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close13.35
Open13.53
Bid13.07 x 3200
Ask13.25 x 2200
Day's Range12.81 - 13.70
52 Week Range3.01 - 22.39
Volume2,069,279
Avg. Volume2,611,182
Market Cap1.149B
Beta (3Y Monthly)2.06
PE Ratio (TTM)N/A
EPS (TTM)-0.68
Earnings DateDec 10, 2018 - Dec 14, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est23.30
Trade prices are not sourced from all markets
  • TheStreet.com2 days ago

    The Rally in Arrowhead Pharmaceuticals Has Been Impressive - Now What?

    In this daily bar chart of ARWR, below, we can see some strong price performance from December with prices rallying from $4 to touch $22 - impressive. The daily On-Balance-Volume (OBV) line shows an interesting rise from November to September. In this weekly bar chart of ARWR, below, we can see a parabolic rally from just $2 back in 2017 to $22 - one heck of a return.

  • Business Wire5 days ago

    Arrowhead Pharmaceuticals Hosts R&D Day on Pipeline of RNAi Therapeutics

    Arrowhead Pharmaceuticals Inc. (ARWR) is hosting a Research & Development (R&D) Day today in New York to discuss its emerging pipeline of RNAi therapeutics that leverage the Company’s proprietary Targeted RNAi Molecule (TRiM™) platform. In addition to senior members of the Arrowhead team, the R&D Day includes, Ira J. Goldberg, M.D., Bronfman Professor of Medicine, Chief of the Division of Endocrinology, Diabetes, and Metabolism, New York University Langone School of Medicine. A live and archived webcast of the event, with slides, may be accessed on the Events and Presentations page under the Investors section of the Arrowhead website.

  • CNBC5 days ago

    Johnson & Johnson tops third-quarter earnings, revenue estimates

    Pharmaceuticals have been fueling J&J's growth while its consumer and medical device businesses have lagged.

  • Business Wire6 days ago

    Arrowhead Pharmaceuticals Files for Regulatory Clearance to Begin Phase 1 Study of ARO-ANG3

    — Arrowhead to host R&D Day October 16, 2018 to discuss ARO-ANG3 and its emerging pipeline of RNAi therapeutics

  • This 1 Stock Could Send the Entire Healthcare Sector Soaring -- or Plunging
    Motley Fool9 days ago

    This 1 Stock Could Send the Entire Healthcare Sector Soaring -- or Plunging

    Find out which earnings report you really need to pay attention to next week.

  • Here's Why Arrowhead Pharmaceuticals Skyrocketed Almost 30% in September
    Motley Fool10 days ago

    Here's Why Arrowhead Pharmaceuticals Skyrocketed Almost 30% in September

    Investors are excited about data for its hepatitis B drug.

  • Business Wire10 days ago

    Arrowhead to Present Late-Breaking Clinical Data on ARO-AAT and ARO-HBV at AASLD Liver Meeting® 2018

    Arrowhead Pharmaceuticals Inc. will make two late-breaking poster presentations at The Liver Meeting® 2018, the Annual Meeting of the American Association for the Study of Liver Disease being held on November 9-13, 2018, in San Francisco.

  • ACCESSWIRE11 days ago

    Major Biotech Announcements Moving the Market

    HENDERSON, NV / ACCESSWIRE / October 10, 2018 / The biotech market is moved by events and announcements. There are a few major events currently impacting the companies highlighted below. Propanc Biopharma, ...

  • Why Arbutus Biopharma Stock Plunged 24.4% Today
    Market Realist12 days ago

    Why Arbutus Biopharma Stock Plunged 24.4% Today

    Today, Arbutus Biopharma (ABUS) stock is trading at $6.87, which is a 24.42% decline from its October 8 closing price of $9.09. Arbutus Biopharma’s closing price on October 8 represents ~111.0% growth from its 52-week low of $4.30 on December 15, 2017. On August 2, Arbutus Pharma hit its 52-week high of $12.60.

  • InvestorPlace12 days ago

    ARWR Stock Sinks After Signing a Big Collaboration Deal

    On the charts, Arrowhead Pharmaceuticals (NASDAQ: ARWR) showed a “double top,” touching around $20 twice between September and October, before crashing down more than 30% in the last week. As value investors will ask after such a drop…what happened? On Oct. 4, Arrowhead announced that it entered into a license and collaboration with Janssen Pharmaceuticals, a unit of Johnson & Johnson (NYSE: JNJ).

  • JNJ’s $3.7 Billion Deal for Hepatitis B Gene Silencing Drug
    Market Realist13 days ago

    JNJ’s $3.7 Billion Deal for Hepatitis B Gene Silencing Drug

    On October 4, Johnson & Johnson (JNJ) announced an exclusive worldwide license agreement with Arrowhead Pharmaceuticals (ARWR) to develop and commercialize the latter’s Phase 1/2 drug candidate for the treatment of chronic Hepatitis B viral infection.

  • How Is Arrowhead Pharmaceuticals Stock Positioned?
    Market Realist13 days ago

    How Is Arrowhead Pharmaceuticals Stock Positioned?

    When the market opened in 2018, Arrowhead Pharmaceuticals stock was selling at $3.69. Cantor Fitzgerald has raised its target price for Arrowhead Pharmaceuticals to $24 from $18. In July, Chardan Capital raised its price target to $24.50 from $17.50.

  • Is Arrowhead Pharmaceuticals, Inc. a Buy on the Dip?
    Motley Fool13 days ago

    Is Arrowhead Pharmaceuticals, Inc. a Buy on the Dip?

    A market beatdown following some good news has investors scratching their heads.

  • J&J Inks Deal With Arrowhead for Promising Liver Candidate
    Zacks16 days ago

    J&J Inks Deal With Arrowhead for Promising Liver Candidate

    Johnson & Johnson (JNJ) signs a licensing pact with Arrowhead to develop the latter's RNAi therapy candidate, ARO-HBV, for treating chronic hepatitis B viral infection. The deal is worth $3.7 billion.

  • Pharma Stock Roundup: PFE to Get New CEO, LLY Presents Impressive Diabetes Data
    Zacks16 days ago

    Pharma Stock Roundup: PFE to Get New CEO, LLY Presents Impressive Diabetes Data

    Pfizer (PFE) CEO, Ian Read to be replaced by present chief operating officer. Pipeline updates from Lilly (LLY), Novartis (NVS), J&J (JNJ) and others.

  • ACCESSWIRE16 days ago

    Today's Research Reports on Trending Tickers: Arrowhead Pharmaceuticals and Amarin

    NEW YORK, NY / ACCESSWIRE / October 5, 2018 / U.S. markets plunged on Thursday as the 10-year U.S. treasury note hit its highest level since 2011, dampening investors' enthusiasm for stocks. The Dow Jones ...

  • Reuters17 days ago

    J&J, Arrowhead in gene-silencing drug deal worth up to $3.7 billion

    Under the deal, J&J's Janssen Pharmaceuticals unit will obtain a worldwide licence for Arrowhead's ARO-HBV drug and an option to collaborate on up to three new RNA interference (RNAi) drugs, which use gene-silencing technology. J&J's investment comes a month after Arrowhead released data from an early trial testing ARO-HBV, dubbed "revolutionary" by analysts who also said the company was positioned to develop a functional cure for Hepatitis B. It also follows the first U.S. approval for an RNAi drug - Alnylam Pharmaceuticals' (ALNY.O) Onpattro - in August that affirmed the gene-silencing class of drugs as a new frontier in the field of medicine.

  • The Wall Street Journal17 days ago

    [$$] Honey, I Shrunk the Biotech Deal

    Arrowhead Pharmaceuticals touted a deal with Johnson & Johnson with a price tag more than the double the company’s market value, but the actual figure may be far smaller.

  • Stocks - Apple, Amazon Fall in Pre-market; Barnes & Noble Surges
    Investing.com17 days ago

    Stocks - Apple, Amazon Fall in Pre-market; Barnes & Noble Surges

    Investing.com - Stocks in focus in pre-market trade Thursday:· Barnes & Noble (NYSE:BKS) stock jumped 21.25% as of 8:20 AM ET (12:20 GMT) after the struggling bookstore chain announced it was exploring a takeover.· Tilray (NASDAQ:TLRY) stock slumped 3.72% after the company announced it was offering $400 million worth of convertible senior notes to be used for working capital, acquisitions and to repay a $9.1 million mortgage on a production facility in British Columbia.· Apple (NASDAQ:AAPL) and Amazon. ...

  • Benzinga17 days ago

    Arrowhead Announces $3.7B License Agreement With Janssen For Gene-Silencing Drug

    Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) develops medicines to treat intractable diseases. Arrowhead announced entrance into a $3.7-billion license and collaboration agreement with Janssen Pharmaceuticals, a unit of Johnson & Johnson (NYSE: JNJ). This funding will consist of $250 million upon closing, as well as an upfront payment from Janssen and a $75 million equity investment from Johnson & Johnson Innovation.

  • J&J, Arrowhead in gene-silencing drug deal worth up to $3.7 billion
    Reuters17 days ago

    J&J, Arrowhead in gene-silencing drug deal worth up to $3.7 billion

    Under the deal, J&J's Janssen Pharmaceuticals unit will obtain a worldwide license for Arrowhead's ARO-HBV drug and an option to collaborate on up to three new RNA interference (RNAi) drugs, which use gene-silencing technology. J&J's investment comes a month after Arrowhead released data from an early trial testing ARO-HBV, dubbed "revolutionary" by analysts who also said the company was positioned to develop a functional cure for Hepatitis B.

  • MarketWatch17 days ago

    UPDATE: Arrowhead Pharma stock surges 19% on news of $3.7 billion license agreement with Janssen

    Arrowhead Pharmaceutics Inc. stock surged 19% in premarket trade Thursday, after the company said it has entered a $3.7 billion license and cooperation agreement with Janssen Pharmaceuticals Inc. to develop and commercialize its ARO-HBV treatment for chronic hepatitis B. As part of the deal, Arrowhead will receive $175 million upon close and Janssen parent Johnson & Johnson Innovation JJDC Inc., a unit of Johnson & Johnson , will buy a $75 million stake priced at $23 a share of Arrowhead common stock. Arrowhead will be eligible to receive up to $1.6 billion in milestone payments and another roughly $1.9 billion in option and milestone payments for reaching three additional targets. The company will also be eligible for tiered royalties on product sales. Janssen will have an exclusive license on the ARO-HBV program, a subcutaneously administered RNAi therapeutic candidate aimed at treating hepatitis B. The deal is expected to close in the fourth quarter. Arrowhead shares have gained 404% in 2018, while the S&P 500 has gained 9%.

  • Business Wire17 days ago

    Arrowhead Enters $3.7 Billion License and Collaboration Agreements with Janssen

    - Upon closing, Arrowhead to receive $250 million, consisting of $175 million upfront payment from Janssen and $75 million equity investment from Johnson & Johnson Innovation – JJDC, Inc. Arrowhead Pharmaceuticals Inc. (ARWR) today announced that it entered into a license and collaboration agreement with Janssen Pharmaceuticals, Inc., part of the Janssen Pharmaceutical Companies of Johnson & Johnson, to develop and commercialize ARO-HBV.

  • Business Wire26 days ago

    Arrowhead Pharmaceuticals to Present at Upcoming October 2018 Conferences

    Arrowhead Pharmaceuticals Inc. today announced that it is scheduled to present at the following upcoming events:

  • Business Wire27 days ago

    Arrowhead Pharmaceuticals to Host R&D Day on Emerging Pipeline of RNAi Therapeutics

    Arrowhead Pharmaceuticals Inc. (ARWR) today announced that it will host a Research & Development (R&D) Day to discuss its emerging pipeline of RNAi therapeutics that leverage its proprietary Targeted RNAi Molecule (TRIMTM) platform on October 16, 2018 in New York City. The R&D Day will feature presentations by Ira Goldberg, M.D. (NYU Langone Medical Center) who will discuss the current treatment landscape and unmet medical need for patients with dyslipidemia and hypertriglyceridemia. Arrowhead's management team will provide an overview of the company’s pipeline of RNAi-based therapeutics.